Expression of miR‑106 in endometrial carcinoma RL95‑2 cells and effect on proliferation and invasion of cancer cells

Li,Xingjun; Yi,Xianghua; Bie,Chuanding; Wang,Zhemin

doi:10.3892/ol.2018.8926

Expression of miR‑106 in endometrial carcinoma RL95‑2 cells and effect on proliferation and invasion of cancer cells

Authors:
- Xingjun Li
- Xianghua Yi
- Chuanding Bie
- Zhemin Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, Chongming Branch Hospital, Affiliated Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 202150, P.R. China, Department of Pathology, Tongji Hospital Affiliated to Tongji University, Shanghai 202150, P.R. China, Department of Pathology, Suizhou Maternal and Child Health‑Care Hospital, Suizhou, Hubei 441300, P.R. China, Department of Orthopaedics, Chongming Branch Hospital, Affiliated Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 202150, P.R. China
Published online on: June 8, 2018 https://doi.org/10.3892/ol.2018.8926
Pages: 2251-2254
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of miR‑106 in endometrial carcinoma RL95‑2 cell line and its effect on proliferation and invasion of cancer cells was investigated. miR‑106 expression vector was constructed and transiently transfected into in vitro cultured RL95‑2 cells of human endometrial carcinoma. Cells were divided into three groups including blank control cells (MOCK group), miR‑106 transfection group (miR‑106 group) and negative control group (siNC group). Reverse-transcription quantitative PCR (RT‑qPCR) was used to detect the expression of miR‑106. Proliferation and in vitro migration of RL95‑2 cells were detected by MTT and scratch assay, and cell apoptosis was detected by flow cytometry. Compared with MOCK and siNC group, cell apoptosis rate was significantly decreased but cell proliferation rate was significantly increased in miR‑106 group (p<0.05). In addition, cell migration and invasion ability was significantly increased in miR‑106 group (p<0.05). Overexpression of miR‑106 can promote proliferation and inhibit apoptosis of endometrial cancer RL95‑2 cells, and miR‑106 may serve as a new target for the treatment of endometrial cancer in the future.

View Figures

View References

1	Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al: ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group: ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41. 2016. View Article : Google Scholar : PubMed/NCBI
2	Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet. 366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
3	van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, et al: POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res. 21:3347–3355. 2015. View Article : Google Scholar : PubMed/NCBI
4	Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, et al: Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst. 107:4022014.PubMed/NCBI
5	Plante M, Touhami O, Trinh XB, Renaud MC, Sebastianelli A, Grondin K and Gregoire J: Sentinel node mapping with indocyanine green and endoscopic near-infrared fluorescence imaging in endometrial cancer. A pilot study and review of the literature. Gynecol Oncol. 137:443–447. 2015. View Article : Google Scholar : PubMed/NCBI
6	Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, et al: Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 28:836–844. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wilczynska A and Bushell M: The complexity of miRNA-mediated repression. Cell Death Differ. 22:22–33. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yuan R, Zhi Q, Zhao H, Han Y, Gao L, Wang B, Kou Z, Guo Z, He S, Xue X, et al: Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma. Tumour Biol. 36:3093–3100. 2015. View Article : Google Scholar : PubMed/NCBI
9	Yen CS, Su ZR, Lee YP, Liu IT and Yen CJ: miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 22:5183–5192. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zheng Z, Zhang Y, Zhang Z, Yang Y and Song T: Effect of miR-106b on invasiveness of pituitary adenoma via PTEN-PI3K/AKT. Med Sci Monit. 23:1277–1285. 2017. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. METHODS. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA and Goodfellow PJ: Polymerase ε (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. Cancer. 121:386–394. 2015. View Article : Google Scholar : PubMed/NCBI
13	Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L and Bae-Jump VL: Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 4:161–173. 2015. View Article : Google Scholar : PubMed/NCBI
14	Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340. 2016. View Article : Google Scholar : PubMed/NCBI
15	Aune D, DA Rosenblatt Navarro, Chan DS, Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV and Norat T: Anthropometric factors and endometrial cancer risk: A systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 26:1635–1648. 2015. View Article : Google Scholar : PubMed/NCBI
16	Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME and Brinton LA: Metabolic syndrome and risk of endometrial cancer in the United States: A study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev. 24:261–267. 2015. View Article : Google Scholar : PubMed/NCBI
17	Schnall-Levin M, Rissland OS, Johnston WK, Perrimon N, Bartel DP and Berger B: Unusually effective microRNA targeting within repeat-rich coding regions of mammalian mRNAs. Genome Res. 21:1395–1403. 2011. View Article : Google Scholar : PubMed/NCBI
18	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
19	Jonas S and Izaurralde E: Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 16:421–433. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang J, Li S, Li L, Li M, Guo C, Yao J and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 13:17–24. 2015. View Article : Google Scholar : PubMed/NCBI
21	Delay C, Mandemakers W and Hébert SS: MicroRNAs in Alzheimer's disease. Neurobiol Dis. 46:285–290. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang X, Wang Z, Yang Y, Chen C, Wang Z, et al: The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget. 6:7000–7010. 2015.PubMed/NCBI